CN104473976A - Application of auricularia auricular polysaccharides in cerebral hemorrhage diseases - Google Patents
Application of auricularia auricular polysaccharides in cerebral hemorrhage diseases Download PDFInfo
- Publication number
- CN104473976A CN104473976A CN201410794366.0A CN201410794366A CN104473976A CN 104473976 A CN104473976 A CN 104473976A CN 201410794366 A CN201410794366 A CN 201410794366A CN 104473976 A CN104473976 A CN 104473976A
- Authority
- CN
- China
- Prior art keywords
- polysaccharides
- reducing
- cerebral hemorrhage
- auricularia auricular
- auricularia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
Abstract
The invention discloses an application method of auricularia auricular polysaccharides in cerebral hemorrhage diseases. In the application method disclosed by the invention, the auricularia auricular polysaccharides belong to fungal polysaccharides, the fungal polysaccharides are macromolecule polymers, have complex bioactivities and functions, and have bioactivities in anti-tumour, immunoregulation, anti-thrombus, anti-ageing, blood sugar-reducing, blood fat-reducing, antioxidant and anti-thrombase aspects and the like. The auricularia auricular polysaccharides (APP) belong to the fungal polysaccharides, have a function of reducing thrombase activity, and have the bioactivities of protecting mitochondrial function and the like while reducing blood fats, reducing blood sugar, resisting tumour and resisting ageing.
Description
Technical field
The present invention relates to the utilization of Auricularia polycose at Cerebral Hemorrhage Disease, belong to medical art.
Background technology
Cerebrovascular disease (CDV) is the disease that in nervous system, sickness rate is higher, has that PD speed is fast, the course of disease recovers heavy characteristics of incidence of disabling slowly, more afterwards.In CDV, about 30% is cerebral hemorrhage (ICH), its disability rate and case fatality rate higher, application dehydrant, reduction intracranial pressure, operation hematoma clearance etc. are had clinically at present for the main method of ICH treatment, part ICH patient early-stage hematoma remove operative treatment, but therapeutic effect and more after neurological functional recovery still not good.Show after deliberation, thrombin directly can pass through cytotoxic effect damaged nerve cells, and destroys blood brain barrier, increases the weight of cerebral tissue gap edema, is the key factor that cerebral edema is formed.
Summary of the invention
The object of the invention is: provide Auricularia polycose at the application method of Cerebral Hemorrhage Disease, can effectively prevention and therapy cerebral hemorrhage and relevant disease, to overcome the deficiencies in the prior art.
Technical scheme of the present invention
Auricularia polycose is at the application method of Cerebral Hemorrhage Disease.
By adopting technique scheme, compared with prior art, fungus polysaccharide is belonged to Auricularia polysaccharide in the present invention, and fungus polysaccharide is a kind of macromolecule polymer, there is complicated biological activity and function, there is many-sided biological activitys such as antitumor, immunomodulating, antithrombotic, defying age, blood sugar lowering, blood fat reducing, antioxidant activity, antithrombase.Auricularia polycose (APP) belongs to fungus polysaccharide, and APP has the effect of reduction thrombin activity, and blood fat reducing, blood sugar lowering, antitumor and defying age have the biological activitys such as protective wire mitochondria function simultaneously.
Detailed description of the invention
The present invention below further describes in detail, but not as any limitation of the invention.
Embodiments of the invention:
Laboratory animal:
Male SD rat, body weight 250-300g, totally 80, monthly age 3-4 month
Main agents: Auricularia polycose, EB, Collagenase V II, Methanamide, 10% chloral hydrate injection
Key instrument:
Precision electronic balance, Constant Temp. Oven, ultraviolet-uisible spectrophotometer, centrifuge, micro-cool injector, optical microscope etc.
Method:
Rat is divided into sham operated rats, model group, low, high dose administration group.Individual administration group is respectively with the Auricularia polycose solution gavage of 100mg/kg and 500mg/kg, all the other two groups give normal saline gavage, 1 times/day, Rat Cerebral hemorrhage Model is prepared after 14 days, micro-cool injector contains 0.4U Collagenase V II and 2 μ l normal saline solutions as the injection of rat RCN, make cerebral hemorrhage mold, sham operated rats operation is the same, but does not add Collagenase V II.Each group of rat after modeling 72 hours, be divided into AB two subgroups at random, after first having carried out neurological deficits score, A subgroup puts to death rat, and take out the complete cerebral tissue of rat, before inserting needle hole, centered by 1MM, Coronal cuts first half hematoma and surrouding brain tissue, for measuring the change of water content, cut hematoma and surrouding brain tissue sheet (about 4-5mm) by crown for residue latter half, carry out HE dyeing, with its tissue pathologies change of observation by light microscope; B subgroup injects azovan blue reactor solution at rat tail vein, it is made to put to death rat in rat body inner loop after at least 2 hours, getting rat hematoma surrouding brain tissue and be about 100MG, amounting to the permeability of solution content comment blood brain barrier by detecting rat cerebral tissue Yi Wensi Laneige.
Conclusion:
Collagenase induction cerebral hemorrhage mold method is simple, reliable results, Auricularia polycose can alleviate the infringement of blood brain barrier after Intracerebral Hemorrhage in Rats, alleviate Cerebral Edema after Cerebral Hemorrhage, alleviate rat afunction, the effect that high dose group Auricularia polycose alleviates Intracerebral Hemorrhage in Rats associated with hydrocephalus is better than low dose group.
Claims (1)
1. Auricularia polycose is in the utilization of Cerebral Hemorrhage Disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410794366.0A CN104473976A (en) | 2014-12-21 | 2014-12-21 | Application of auricularia auricular polysaccharides in cerebral hemorrhage diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410794366.0A CN104473976A (en) | 2014-12-21 | 2014-12-21 | Application of auricularia auricular polysaccharides in cerebral hemorrhage diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104473976A true CN104473976A (en) | 2015-04-01 |
Family
ID=52748678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410794366.0A Pending CN104473976A (en) | 2014-12-21 | 2014-12-21 | Application of auricularia auricular polysaccharides in cerebral hemorrhage diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104473976A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1485089A (en) * | 2002-09-25 | 2004-03-31 | 桂镜生 | Jelly fungi blood fat clearing capsule |
| US20110206721A1 (en) * | 2010-02-19 | 2011-08-25 | Vijaya Nair | Fermented soy nutritional supplements including mushroom components |
-
2014
- 2014-12-21 CN CN201410794366.0A patent/CN104473976A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1485089A (en) * | 2002-09-25 | 2004-03-31 | 桂镜生 | Jelly fungi blood fat clearing capsule |
| US20110206721A1 (en) * | 2010-02-19 | 2011-08-25 | Vijaya Nair | Fermented soy nutritional supplements including mushroom components |
Non-Patent Citations (3)
| Title |
|---|
| 张秀娟等: "黑木耳多糖药理学研究进展", 《中国微生态学杂志》 * |
| 王冲: "黑木耳多糖对脑出血大鼠脑水肿作用的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 王冲等: "黑木耳多糖对脑出血大鼠脑组织的保护作用", 《中国老年学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beheshti et al. | Therapeutic effect of frankincense in a rat model of Alzheimer’s disease | |
| MX352950B (en) | Method of treating neurological conditions with cardiac glycosides. | |
| WO2010129138A3 (en) | Phosphorylated and phosphonated pyrone analogs for therapeutic treatment | |
| Jiang et al. | Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis | |
| WO2015152416A1 (en) | Ocular hypotensive agent | |
| Wei et al. | Neuroprotective effect of verbascoside on hypoxic-ischemic brain damage in neonatal rat | |
| Choi et al. | Interim Report about The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung | |
| Liu et al. | Antiallodynic and anti-hyperalgesia effects of Tiliacora triandra against cisplatin-induced peripheral neuropathy | |
| Wang et al. | Inhibitive effect on apoptosis in splenic lymphocytes of mice pretreated with lingzhi (Ganoderma lucidum) spores | |
| CN103211869B (en) | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof | |
| CN101152208A (en) | Application of brown seaweed polyoses sulfate in preparing medicament for treating senile dementia | |
| CN104473976A (en) | Application of auricularia auricular polysaccharides in cerebral hemorrhage diseases | |
| CN104739831B (en) | Application of the berberine in the medicine for preparing treatment B cell lymphoma | |
| CN104906088B (en) | Application of the berberine in the medicine for preparing treatment t cell lymphoma | |
| US8182844B2 (en) | Use of Clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
| CN107854620B (en) | Traditional Chinese medicine composition for improving cognitive dysfunction after brain injury and application thereof | |
| Min et al. | Clinical research into Qufeng Zhidong Recipe used to treat 31 children with tic disorder | |
| CN102860495B (en) | Anti-anoxia immunity-improving health food and preparation method thereof | |
| CN104130232B (en) | The method of purification of a kind of EGCG and the EGCG of acquisition and pharmaceutical composition | |
| Sahraei et al. | Investigation of the scopolamine effect on acetylcholinesterase activity | |
| CN104857039A (en) | New purpose of embelia parviflora Wall. for preparing medicines for treating Alzheimer's diseases | |
| CN103142666A (en) | Health-care composition | |
| CN103830685B (en) | A kind of medicine for the treatment of facial neuritis | |
| CN103372044A (en) | Medicament for treating hemicranias, and application thereof in preparation of nose drop for treating hemicranias | |
| CN105194504B (en) | The more capsule that relaxes is preparing the application having in neuroprotective medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150401 |